title: Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells: implications for use in immunocompromised patients.
abstract: Bryostatin 1 is a novel anti-tumor agent currently undergoing clinical trial. We investigated the effect of this drug on B-lymphocyte cell lines that carry the Epstein-Barr virus and found that it induces these latently infected cells into the production of transforming virus particles over a wide range of concentrations. These results may have clinical implications, particularly with regard to the use of the drug in the immunocompromised patient.
authors.affiliation: CRC Department of Molecular Biology, Paterson Institute for Cancer Research, Christie CRC Cancer Centre, Manchester, UK.
authors.forename: J P
authors.initials: JP
authors.lastname: Stewart
authors.forename: A T
authors.initials: AT
authors.lastname: McGown
authors.forename: J
authors.initials: J
authors.lastname: Prendiville
authors.forename: G R
authors.initials: GR
authors.lastname: Pettit
authors.forename: B W
authors.initials: BW
authors.lastname: Fox
authors.forename: J R
authors.initials: JR
authors.lastname: Arrand
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000382:microbiology*; D054713:Bryostatins; D002472:Cell Transformation, Viral / Q000187:drug effects; D004854:Herpesvirus 4, Human / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D016867:Immunocompromised Host; D007783:Lactones / Q000494:pharmacology* / Q000627:therapeutic use; D018942:Macrolides; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D017735:Virus Latency / Q000187:drug effects*; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D054713:Bryostatins; D007783:Lactones; D018942:Macrolides; C046785:bryostatin 1; D013755:Tetradecanoylphorbol Acetate